bims-polgdi Biomed News
on POLG disease
Issue of 2026–11–15
27 papers selected by
Luca Bolliger, lxBio



  1. Genome Biol. 2026 Aug 13. pii: 351. [Epub ahead of print]27(1):
      Recent development of mitochondrial DNA (mtDNA) editors has made it possible to generate experimental models carrying patient-relevant mtDNA mutations, characterize disease-associated phenotypes in cells and animals, and directly correct pathogenic variants in vivo. Here, we summarize the current landscape of mtDNA base editors and discuss key considerations for their application to mitochondrial disease model generation, including target selection, cross-species conservation, editing window constraints, strand bias, sequence-context dependence, and the balance between editing efficiency and safety. We further review strategies for validating mtDNA-edited models at functional, molecular, and organismal levels, and highlight recent studies demonstrating therapeutic rescue in animal models.
    DOI:  https://doi.org/10.1186/s13059-026-04244-2
  2. Yale J Biol Med. 2026 Sep;99(3): 521-539
      Mitochondrial dysfunction is increasingly recognized as a shared mechanism across neurological disease. Specifically, impaired oxidative phosphorylation, oxidative stress, and mitochondrial DNA damage are factors in primary mitochondrial disorders and major neurodegenerative diseases such as Parkinson, Alzheimer, and Huntington diseases, and amyotrophic lateral sclerosis. This review surveys the mechanisms driving mitochondrial dysfunction and evaluates the current landscape of gene-editing technologies developed to address them. We examine mitochondria-targeted editors and nuclear-targeted editors, examining the editing capability, delivery constraints, and off-target risk of each. Heteroplasmy-shifting nucleases currently offer the strongest in vivo evidence for mtDNA-directed therapy, while base editors extend correction to homoplasmic mutations at the cost of a narrower editing scope and off-target editing. Nuclear editing platforms avoid the mitochondrial gRNA import barrier entirely, allowing current technologies to achieve the most progress toward functional, behavioral rescue in animal models. Across all platforms, delivery efficiency, off-target specificity, and translation from rodent to primate models remain unresolved barriers to clinical application. Gene editing for mitochondrial dysfunction is highly creditable as a precision therapy for genetically defined disease subsets, including primary mitochondrial disease and other neurodegenerative disorders with a known nuclear driver, rather than as a universal strategy for sporadic neurodegeneration, where mitochondrial dysfunction arises from multifactorial and poorly localized causes.
    Keywords:  Adeno-Associated Virus; Base Editing; CRISPR-Cas9; Gene Editing; Mitochondrial DNA; Mitochondrial Dysfunction; Neurodegenerative Disease; Nuclear DNA; Oxidative Phosphorylation; Reactive Oxygen Species
    DOI:  https://doi.org/10.59249/AFKC3347
  3. Yale J Biol Med. 2026 Sep;99(3): 576-599
      Pathogenic mutations in mitochondrial DNA or nuclear genes encoding mitochondrial proteins essential for mitochondrial function give rise to mitochondrial diseases, a highly heterogeneous group of inherited multisystemic disorders. These genetic defects impair the respiratory chain and disrupt oxidative phosphorylation, resulting in critical adenosine triphosphate depletion and tissue-specific energy failure, predominantly affecting high-energy organs such as the brain, heart, and skeletal muscle. Disease pathogenesis is shaped by heteroplasmy thresholds and is further exacerbated by elevated reactive oxygen species, aberrant calcium signaling, and defective mitophagy. Although next-generation sequencing and biochemical profiling have significantly transformed diagnostic frameworks, these progressive metabolic disorders have historically been managed primarily with supportive or palliative care. Driven by precision medicine, the therapeutic paradigm has recently shifted toward genetic and organelle-targeted interventions. Advanced mitochondrial genome-editing platforms, including zinc-finger nucleases, transcription activator-like effector nucleases, and DddA-derived cytosine base editors, enable precise elimination or correction of mutant mitochondrial DNA variants, thereby modulating heteroplasmy. Concurrently, metabolic regulatory agents, mitochondria-targeted peptides, and organelle transfer techniques, encompassing germline mitochondrial replacement therapy to prevent maternal transmission and mitochondrial transplantation for tissue regeneration, are being actively investigated. Despite promising preclinical outcomes, clinical translation remains constrained by challenges in safe delivery, off-target effects, and ethical concerns associated with germline modification. This review bridges the gap between fundamental molecular pathology and cutting-edge therapeutic strategies, highlighting multidisciplinary approaches poised to transform mitochondrial disease management from symptomatic care toward prevention and disease-modifying intervention.
    Keywords:  Gene therapy; Genome editing; Mitochondrial DNA mutations; Mitochondrial diseases; Mitochondrial dysfunction; Mitochondrial replacement therapy; Therapeutic innovation; precision medicine
    DOI:  https://doi.org/10.59249/VSCB1173
  4. Methods Mol Biol. 2027 ;3105 265-278
      Mitochondrial-wide association studies (MiWAS) extend genome-wide association frameworks to systematically test mitochondrial DNA variants for their associations with aging-related phenotypes. Unlike nuclear DNA, the mitochondrial genome is maternally inherited, lacks recombination, and encodes core components of oxidative phosphorylation, making it central to energy metabolism and cellular stress responses. This chapter provides a comprehensive protocol for conducting MiWAS using population-based aging cohorts, with a focus on practical implementation using publicly available datasets such as the Health and Retirement Study. We describe essential steps, including obtaining institutional approvals and data access, preparing phenotype files with appropriate covariates, extracting mitochondrial variants from genotype arrays, performing ethnic-stratified association testing, and interpreting results with multiple testing corrections. Key considerations include accounting for population stratification through mitochondrial genetic ancestry, selecting appropriate minor allele frequency thresholds, and validating findings through sensitivity analyses and replication. By making methods to assess mitochondrial genetic variation, such as MiWAS, accessible to aging researchers, this opens new opportunities to identify genetic determinants of longevity, age-related disease risk, and mitochondrial-nuclear interactions that shape healthy aging.
    Keywords:  Association studies; Ethnicity; Human data; Mitochondrial genetics; SNPs
    DOI:  https://doi.org/10.1007/978-1-0716-5703-4_15
  5. Mol Med Rep. 2027 Jan;pii: 10. [Epub ahead of print]35(1):
      Mitochondrial proteostasis is essential for maintaining organellar integrity, metabolic adaptation and cellular survival under physiological and stress conditions. Among mitochondrial quality control mechanisms, Lon peptidase 1 (LONP1) is an ATP‑dependent AAA+ serine protease localized predominantly in the mitochondrial matrix and plays a central role in the recognition and degradation of damaged or misfolded proteins. Recent structural, molecular and multi‑omics studies have expanded our understanding of LONP1 beyond proteolysis, implicating it in protein quality control, mitochondrial DNA maintenance, metabolic regulation and responses to oxidative and cellular stress. Increasing evidence also indicates that LONP1 functions are highly dependent on cellular and disease context, with both loss and gain of LONP1 activity associated with distinct pathological outcomes. The present review integrated recent structural and functional advances to establish a structure‑function framework for understanding how LONP1 coordinates proteolytic and chaperone‑like activities and how these functions are shaped by cellular and disease context. The present review further examined its roles in metabolic, neurodegenerative, reproductive, cardiovascular and malignant diseases, with particular emphasis on the context‑dependent consequences of LONP1 dysregulation and its emerging therapeutic potential. Finally, the present review highlighted unresolved questions concerning substrate recognition and specificity, the relative contributions of protease and chaperone‑like functions, disease‑specific directionality and the safety and feasibility of therapeutic modulation. These challenges need to be addressed to establish the functional and translational boundaries of LONP1.
    Keywords:  Lon peptidase 1; diseases1; mitochondrial quality control; oxidative stress; proteostasis
    DOI:  https://doi.org/10.3892/mmr.2026.14068
  6. Int J Mol Sci. 2026 Nov 06. pii: 9949. [Epub ahead of print]27(21):
      Mitochondrial DNA (mtDNA) encodes essential components of oxidative phosphorylation and can stimulate innate immunity when released from mitochondria. Its genetic and immunological functions provide a rationale for investigating mtDNA abnormalities in idiopathic inflammatory myopathies (IIMs), where muscle dysfunction and inflammation coexist. Large-scale deletions and depletion have been documented in inclusion body myositis and polymyositis with mitochondrial pathology, while dermatomyositis studies reveal regional depletion and oxidative modifications in distinct biological compartments. These findings raise the possibility that mtDNA abnormalities contribute to both impaired mitochondrial function and inflammatory signaling. This review integrates subtype-specific findings with mechanistic studies of mtDNA release, DNA sensing, and inflammasome activation in IIM-related and non-IIM systems. It evaluates the evidence for mtDNA-based biomarkers and therapies targeting mitochondrial injury or downstream inflammation. The reported clinical benefits do not establish mtDNA-specific therapeutic effects. Defining how mitochondrial genome abnormalities and inflammatory signaling interact within each subtype is a priority for biomarker validation and therapeutic research.
    Keywords:  NLRP3 inflammasome; TLR9; biomarkers; cGAS–STING pathway; idiopathic inflammatory myopathies; mitochondrial DNA; therapeutic strategies
    DOI:  https://doi.org/10.3390/ijms27219949
  7. Doc Ophthalmol. 2026 Nov 09.
      Hereditary optic neuropathies, such as Leber's hereditary optic neuropathy (LHON), remain a focus of active research. Diagnostic challenges and severe clinical consequences often result in atypical presentations, creating significant obstacles for neuro-ophthalmology. The field has garnered increased attention due to advances in molecular biology and genetic engineering. Pathogenic variants in mitochondrial DNA (mtDNA) and nuclear DNA disrupt oxidative phosphorylation, reduce adenosine triphosphate production, and increase reactive oxygen species generation, to which retinal ganglion cells are particularly vulnerable. Rare genetic variants have been identified in LHON and related mitochondrial disorders, including mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes and Leigh syndrome. Phenotypic heterogeneity, variable heteroplasmy levels, and limited sensitivity of targeted genetic testing complicate the detection and interpretation of rare variants. As a result, comprehensive next-generation sequencing is increasingly necessary for accurate molecular diagnosis and timely treatment initiation. Recent therapeutic interventions include genotype-specific approaches, such as adeno-associated virus serotype 2-mediated allotopic expression, and genotype-independent therapies, such as idebenone. Diagnostic standards for mitochondrial optic neuropathies have shifted from focusing solely on the three primary pathogenic mtDNA variants to a broader molecular diagnostic framework. Future research should prioritize mtDNA sequencing in cases with inconclusive diagnoses using conventional methods, incorporate mitochondrial and nuclear genomics, and leverage artificial intelligence-based approaches. Accurate identification and classification of rare variants, together with a deeper understanding of their phenotypic consequences, will facilitate the development of individualized therapeutic strategies to prevent further visual decline. This review outlines potential directions for multifaceted treatment strategies in patients with rare LHON-associated variants and critically evaluates current evidence regarding the clinical significance of rare mitochondrial and nuclear genetic variants in LHON and related mitochondrial optic neuropathies.
    Keywords:  Leber hereditary optic neuropathy; Mitochondrial optic neuropathies; Rare genetic variants; Retinal ganglion cells
    DOI:  https://doi.org/10.1007/s10633-026-10166-y
  8. Orphanet J Rare Dis. 2026 08 14. pii: 414. [Epub ahead of print]21(1):
       BACKGROUND: The lack of treatments for patients with a rare disease calls for innovative approaches in drug development. A potential solution to accelerate therapy development is to find new therapeutic uses for existing drugs, i.e. drug repurposing. One way of advancing drug repurposing is to focus on similarities in the molecular and clinical manifestations across multiple rare diseases, by studying drug repurposing candidates in induced pluripotent stem cell (iPSC) models and subsequently grouping diseases in basket trials composed of multiple sub-studies. However, the absence of a single route to navigate the regulatory process, in combination with limited regulatory experience in academia poses a challenge for this approach. To provide more insight into the perceived regulatory challenges and opportunities for basket trials in drug repurposing for rare diseases, a multi-stakeholder dialogue was organised in March 2025. The aim of this dialogue was to contribute to a better alignment of stakeholder perspectives to accelerate therapy development for rare diseases, by identifying and mapping challenges and opportunities in three regulatory scenarios for basket trials in drug repurposing for rare diseases.
    RESULTS: In total, 28 experts (regulatory, preclinical, clinical, patient, industry, HTA, and other) from eight European countries participated in an interactive online meeting. Thematic analysis of the meeting content showed the most important challenges and opportunities in navigating the regulatory scenarios, covering themes such as preclinical evidence in iPSC models, design of basket trials, involvement of patient organisations, regulatory roles and responsibilities, pharmaceutical product development, HTA and reimbursement, and societal views on repurposed drugs.
    CONCLUSIONS: This multi-stakeholder dialogue highlights the continued need for 1) early regulatory guidance for academic innovators, 2) a (re)calibration of regulatory roles and responsibilities, and 3) early creation of collaborative spaces involving patient organisations, HTA bodies and marketing authorisation holders in the development process to optimize the potential of innovative methods. This multi-stakeholder alignment is essential for the compliant adoption of iPSC models and clinical basket trial designs as promising accelerators for drug repurposing in rare diseases.
    CLINICAL TRIAL NUMBER: Not applicable.
    Keywords:  Basket trial; Drug repurposing; Marketing authorisation; Multi-stakeholder dialogue; Pharmaceuticals; Rare diseases; Regulation; SIMPATHIC; Signature-based; iPSC
    DOI:  https://doi.org/10.1186/s13023-026-04551-8
  9. Orphanet J Rare Dis. 2026 08 13. pii: 409. [Epub ahead of print]21(1):
       BACKGROUND: Rare diseases affect millions globally but remain poorly understood due to low prevalence and fragmented healthcare responses. Patients face long diagnostic delays, known as the "diagnostic odyssey", due to limited knowledge and awareness among healthcare professionals. This scoping review examines healthcare professionals' knowledge and awareness of rare diseases. Findings highlight critical educational and systemic gaps across disciplines. Addressing these deficits is essential to improve early recognition, care coordination, and health outcomes for rare disease populations.
    METHODS: This scoping review followed Arksey and O'Malley's five-stage framework, enhanced by the Joanna Briggs Institute (JBI) methodology and PRISMA-ScR guidelines. The review mapped existing literature guided by the PCC framework. A comprehensive search strategy was developed and executed across four databases, CINAHL, Medline, PubMed, and Scopus, along with grey literature sources. After removing duplicates, 4539 records were screened, and 25 studies met the inclusion criteria. Data was charted and synthesised thematically using an inductive approach to identify key findings and gaps in professional education and awareness.
    RESULTS: Twenty-five studies from 2015 to 2025 were included, spanning diverse countries and healthcare professions. Most used cross-sectional surveys to assess knowledge, awareness, and confidence regarding rare diseases. Overall, healthcare professionals demonstrated limited knowledge, poor familiarity with rare disease definitions, and low use of specialist resources. Variability was observed across professional groups, with general practitioners and nurses demonstrating lower knowledge than specialists. Education and training were widely reported as insufficient, with gaps evident across both undergraduate and clinical settings. Despite low objective knowledge, many participants overestimated their competence. These knowledge gaps were associated with challenges in diagnosis and management, including delayed recognition of rare diseases. A strong demand for improved rare disease education and accessible guidelines was consistently expressed.
    CONCLUSION: Despite growing recognition of rare diseases as a public health priority, healthcare systems worldwide lack structured education, standardised guidelines, and accessible resources. The review calls for further research, urgent educational reform, improved digital resources, and targeted policy changes to integrate rare disease education into healthcare curricula and enhance clinical support. Addressing these gaps will improve care, facilitate earlier diagnoses, and ensure more equitable outcomes for rare disease patients.
    Keywords:  Awareness; Continuing education; Healthcare professional; Knowledge; Medical education; Rare developmental defect; Rare disorder; Rare genetic disorder; Scoping review
    DOI:  https://doi.org/10.1186/s13023-026-04520-1
  10. Yale J Biol Med. 2026 Sep;99(3): 442-451
      Viruses exploit mitochondrial biogenesis, dynamics, and mitophagy-complex processes that influence mitochondrial morphology, metabolism, and innate immune responses-to evade immunity, enhance replication, and facilitate infection. However, acute and nonacute viral infections induce mitochondrial dysfunction through distinct mechanisms. Unlike acute infections, nonacute viral infections dynamically regulate mitochondrial biogenesis by targeting key molecular pathways to support viral replication. Additionally, chronic infections promote mitochondrial fission either directly or indirectly by altering the expression of fission and fusion proteins. During acute infection, early mitophagy benefits viruses by removing damaged mitochondria, suppressing apoptosis, and fostering replication. In contrast, excessive or incomplete mitophagy in later nonacute stages may deplete cellular energy and impair mitochondrial function, ultimately triggering apoptosis and viral release. Consequently, therapies such as mitochondrial biogenesis modulators, mitophagy agonists, and mitochondria-targeted antioxidants could be effective against chronic viral infections. In this review, molecular mechanisms of nonacute viral mitochondrial remodeling are summarized, and corresponding regulatory approaches to enhance therapeutic outcomes are highlighted.
    Keywords:  apoptosis; fission; mitochondrial biogenesis; mitophagy; nonacute viral infections
    DOI:  https://doi.org/10.59249/SMXA2056
  11. Gene Ther. 2026 Nov 13.
      Rare diseases collectively impose a substantial health burden, yet most lack disease-modifying treatments. We conducted a registry-based cross-sectional analysis of gene therapy development for rare diseases using U.S. Food and Drug Administration (FDA) product records, Orphanet classifications, and clinical trial records retrieved through Gene Therapy Net, whose core data are derived from ClinicalTrials.gov, with an October 2025 cutoff. Of 1464 registered studies, 646 (44.13%) addressed 175 distinct rare diseases. Annual initiation of rare disease studies increased from 21 in 2015 to 73 in 2024. Hemophilia A and B, retinitis pigmentosa, Duchenne muscular dystrophy, and sickle cell disease were the most frequently studied indications. Within the rare disease cohort, 547 studies (84.67%) were interventional, 408 (63.16%) were classified as early phase I, phase I, or phase I/II, and 402 (62.23%) permitted pediatric enrollment. The United States was listed as a study location in 410 studies (63.47%). Of 30 approved gene therapy products identified, 24 (80.00%) had at least one rare disease indication, collectively covering 16 indications. Rare diseases constituted a substantial component of gene therapy development, with an expanding clinical research portfolio and established regulatory approvals. The predominance of early-phase studies and geographic concentration highlight priorities for later-phase evaluation and broader international participation.
    DOI:  https://doi.org/10.1038/s41434-026-00658-6
  12. Cell Rep Methods. 2026 Nov 11. pii: S2667-2375(26)00367-X. [Epub ahead of print] 101666
      Preventing transmission of maternally inherited mitochondrial diseases remains a major challenge in reproductive medicine. Nuclear transfer (NT) offers a promising strategy by replacing mutant mitochondrial DNA (mtDNA) while preserving the nuclear genome; nevertheless, residual mtDNA carryover can persist in reconstructed embryos and potentially expand, leading to disease recurrence. Using a heteroplasmic mouse model harboring the pathogenic m.5024C>T mutation, we evaluated two approaches to reduce mtDNA carryover following pronuclear transfer (PNT): mitochondrially targeted transcription activator-like effector nucleases (mitoTALENs) and induced mitophagy. PNT alone markedly lowered heteroplasmy, reducing mutant mtDNA from 68.5% to 2.4%, on average. Application of mitoTALENs post-PNT further reduced residual mutant mtDNA below 1%, with levels as low as 0.2%, without compromising embryonic development. In contrast, mitophagy induction via SQSTM1 overexpression failed to reduce heteroplasmy, consistent with inefficient lysosomal recruitment in embryos. Additionally, we validated digital PCR (dPCR) as a sensitive and robust method for quantifying mtDNA copy number and low-level heteroplasmy.
    Keywords:  CP: biotechnology; CP: developmental biology; MitoTALENs; digital PCR; heteroplasmy; mitochondrial disease; mitophagy; pronuclear transfer
    DOI:  https://doi.org/10.1016/j.crmeth.2026.101666
  13. Fa Yi Xue Za Zhi. 2026 Aug 25. pii: 1004-5619(2026)04-0310-08. [Epub ahead of print]42(4): 310-317
       OBJECTIVES: To investigate the genetic characteristics of homoplasmic and heteroplasmic mitochondrial DNA (mtDNA) variations in four-generation maternal lineages.
    METHODS: Buccal swabs were collected from 23 individuals belonging to 4 four-generation maternal lineages. DNA was extracted, and mtDNA whole genome libraries were constructed. Sequencing was performed using the Ion S5 XL sequencing system, followed by sequence alignment and variation analysis.
    RESULTS: Following quality control and analysis of obtained mtDNA whole genome sequencing data, the sequencing coverage reached 99.73%, and the average sequencing depth was 3 458×. A total of 939 genetic variations were observed, including 883 point mutations, 36 insertion/deletion variations, and 20 heteroplasmic variations. No differentiated homoplasmic point mutations were found in the mtDNA sequences of individuals from the same maternal lineage, whereas inconsistent point heteroplasmies (PHPs) were detected.
    CONCLUSIONS: Mitochondrial PHP variations can change during inheritance, and there is a risk of using PHP differences as an exclusion criterion for determining whether individuals come from the same maternal lineage. When comparing mtDNA sequences, if the same PHP is observed in two samples with identical haplotypes and its major and minor alleles are consistent, it can be considered as enhanced evidence to determine that the two samples come from the same maternal lineage.
    Keywords:  forensic genetics; heteroplasmic variation; matrilineal relationship identification; mitochondrial DNA (mtDNA); next-generation sequencing; whole genome sequencing
    DOI:  https://doi.org/10.12116/j.issn.1004-5619.2024.540401
  14. Front Aging Neurosci. 2026 ;18 1914316
      Parkinson's disease (PD) is a neurodegenerative disorder for which advancing age is the major risk factor. Aging and PD share several features, including chronic neuroinflammation and pathological protein accumulation. This overlap suggests that mechanisms driving the aging process may also contribute to the onset and progression of PD. In this narrative review, we examine mitochondrial dysfunction as a shared feature of aging and PD, focusing on energy production, calcium buffering, apoptosis, inflammation, and reactive oxygen species (ROS) generation. The literature reviewed here suggests shared alterations in mitochondrial dynamics, increased mitochondrial DNA (mtDNA) instability, NAD+ depletion, Complex I inhibition, redox imbalance, and disrupted calcium homeostasis. We also summarize mitochondria-targeted interventions investigated in PD.
    Keywords:  Parkinson's disease; aging; calcium homeostasis; mitochondria; mitochondrial dynamics; oxidative phosphorylation
    DOI:  https://doi.org/10.3389/fnagi.2026.1914316
  15. Bioorg Med Chem Lett. 2026 Nov 13. pii: S0960-894X(26)00282-9. [Epub ahead of print] 130815
      Chemoproteomic mapping of ligandable lysine and tyrosine residues has expanded covalent drug discovery and chemical biology beyond cysteine. Analysis of 950 ligandable proteins revealed a significant enrichment of genes associated with mitochondrial DNA depletion syndromes (MDDS). Several MDDS-associated proteins contained ligandable lysine or tyrosine residues, highlighting opportunities for therapeutic intervention in genetically validated mitochondrial disease targets. We discuss two representative examples: SUCLG1, which contains a ligandable active-site lysine that may enable covalent inhibition, and AGK, which contains a ligandable tyrosine that may provide an allosteric strategy for modulating mitochondrial and immune signaling. These findings extend emerging links between chemoproteomic ligandability and human genetics to mitochondrial DNA depletion disorders, suggest new opportunities for chemical probe and drug discovery, and provide a framework for prioritizing disease-relevant targets identified through covalent chemoproteomics.
    Keywords:  AGK; Chemoproteomics; Mitochondrial DNA; SUCLG1
    DOI:  https://doi.org/10.1016/j.bmcl.2026.130815
  16. BMC Med Genomics. 2026 Aug 11. pii: 173. [Epub ahead of print]19(1):
       BACKGROUND: Pediatric rare diseases are clinically and genetically heterogeneous, often resulting in delayed molecular diagnosis. In routine clinical practice, diagnostic outcomes reflect the combined performance of complete workflows that may differ in sample source, sequencing depth, laboratory procedures, bioinformatics, interpretation, and reporting. We compared two independent clinical diagnostic workflows applied in parallel to the same Albanian pediatric cohort.
    METHODS: Seventy-two patients with suspected rare genetic disorders underwent genome sequencing (GS) from saliva or buccal swabs at approximately 30 × mean depth and exome sequencing (ES) from dried blood spots, with more than 98% of target bases covered at ≥20×. The ISO-accredited laboratories independently performed sequencing, analysis, interpretation, and reporting. We assessed report-level primary diagnostic yield, paired outcomes, variant classes, discordant findings, and laboratory-reported secondary/additional findings. Variants of uncertain significance (VUS) were excluded from yield. Raw data were not centrally reanalyzed, and sample types were not cross-tested.
    RESULTS: At least one workflow reported a pathogenic or likely pathogenic finding interpreted as a primary molecular diagnosis in 29/72 patients (40.3%; 95% CI, 28.9-52.5). GS reports contained primary diagnoses for 26/72 patients (36.1%; 95% CI, 25.1-48.3) and ES reports for 16/72 (22.2%; 95% CI, 13.3-33.6). Primary outcomes were concordant in 56 participants (13 positive and 43 negative) and discordant in 16 (13 GS-only and three ES-only). The GS laboratory also reported 13 secondary/additional variant-level rows in 11 patients (12 P/LP rows and one VUS row), including seven patients without a primary diagnosis.
    CONCLUSIONS: The workflows produced overlapping but non-identical clinical reports, and neither workflow was comprehensive. The observed differences cannot be attributed to sequencing technology alone because sample type, depth, laboratory, bioinformatics, prioritization, and reporting scope were not harmonized. Implementation decisions should integrate diagnostic contribution with cost, turnaround time, infrastructure, workforce, governance, and local feasibility.
    Keywords:  Albania; Diagnostic workflow; Diagnostic yield; Exome sequencing; Genome sequencing; Pediatric genomics; Rare diseases; Secondary findings
    DOI:  https://doi.org/10.1186/s12920-026-02450-2
  17. MedComm (2020). 2026 Nov;7(11): e71011
      CRISPR-Cas genome editing represents one of the most transformative advances in modern molecular biology, enabling programmable site-specific genetic modification that has revolutionized functional genomics and precision therapeutic development. Beyond canonical Cas9 nucleases, the CRISPR toolkit has diversified into precision base editors, prime editors, CRISPR-associated transposases, and Cas12/Cas13 RNA-targeting effectors, each with distinct mechanistic properties. Clinically, ex vivo CRISPR therapies for hemoglobinopathies have secured regulatory approval, while base editing, prime editing, and in vivo Chimeric Antigen Receptor (CAR)-T candidates are advancing through trials for a broad spectrum of hematologic, oncologic, and rare genetic disorders. However, existing reviews largely address technical innovation or clinical translation in isolation, lacking a holistic, up-to-date synthesis of the full bench-to-bedside trajectory of CRISPR technology. This review systematically dissects the molecular mechanisms, advantages, and limitations of core CRISPR editing platforms; summarizes pivotal clinical data across hemoglobinopathies, CAR-T immunotherapy, muscular dystrophy, cystic fibrosis, cardiometabolic diseases and rare monogenic diseases; evaluates delivery systems including lipid nanoparticles and viral vectors; and discusses key translational barriers such as off-target genotoxicity and immunogenicity alongside emerging optimization strategies. This work provides a holistic bench-to-bedside framework for CRISPR research, offering critical insights to advance next-generation precision genetic medicine.
    Keywords:  CRISPR delivery; CRISPR‐Cas9; base editing; clinical translation; gene therapy; genome editing; prime editing
    DOI:  https://doi.org/10.1002/mco2.71011
  18. Eur J Hum Genet. 2026 Nov;34(11): 1595-1596
      
    DOI:  https://doi.org/10.1038/s41431-026-02264-x
  19. Epilepsy Behav. 2026 Nov 12. pii: S1525-5050(26)00489-0. [Epub ahead of print]186 111368
       BACKGROUND: Inborn errors of metabolism (IEM) are an under-recognised cause of childhood epilepsy. Early diagnosis is critical because specific treatments can substantially alter the disease course.
    METHODS: We performed a retrospective study on 21,072 children evaluated for epilepsy in two Child Neurology referral centres in Eastern Sicily (i.e. Messina, Catania, and Enna) between January 2001 and December 2025. Medical records were reviewed to identify patients with a confirmed IEM diagnosis. Clinical, electrophysiological, neuroimaging, and treatment data were collected and analysed.
    RESULTS: Fifty-seven children (0.27%) had a co-diagnosis of epilepsy and IEM (28 males, 29 females). Lysosomal storage disorders were the most common category (31.6%), followed by aminoacidopathies (22.8%), mitochondrial disorders (15.8%), congenital disorders of glycosylation (CDG, 12.3%), and organic acidaemias (7.0%). Seizure onset occurred before the age of three years in 83.3% of IEM cases, compared with 27.6% of children with non-metabolic epilepsy (OR 12.3; 95% CI 6.2-24.4; p < 0.001). Diagnostic delay exceeded 3.5 years from first seizure in half the cohort. Approximately 50% of patients showed drug-resistant epilepsy despite multi-drug anti-seizure medication therapy.
    CONCLUSIONS: IEM should be systematically considered in any child presenting with epilepsy, particularly when onset occurs in the first three years of life. A structured stepwise diagnostic approach can substantially reduce diagnostic delay and facilitate access to disease-specific therapies.
    Keywords:  Anti-seizure medication resistance; Childhood epilepsy; Congenital disorders of glycosylation; Diagnostic delay; Inborn errors of metabolism; Lysosomal storage disorders; Metabolic epilepsy; Mitochondrial disease; Newborn screening; Paediatric neurology
    DOI:  https://doi.org/10.1016/j.yebeh.2026.111368
  20. Hum Genomics. 2026 Aug 14. pii: 159. [Epub ahead of print]20(1):
       BACKGROUND: Traditional molecular diagnosis of rare genetic diseases often struggles with complex genotype-phenotype relationships, such as pleiotropy and locus heterogeneity. Despite advances in next-generation sequencing, variant interpretation remains a major bottleneck, frequently requiring labor-intensive expert review to establish phenotypic specificity. To address this challenge, we developed GenPhenia, a deep learning-based framework designed to assist phenotype-driven gene prioritization using clinical features encoded with the Human Phenotype Ontology (HPO).
    RESULTS: GenPhenia leverages large-scale synthetic clinical history datasets and a graph neural network architecture with message-passing strategies combined with BERT-based phenotype embeddings to learn phenotype-gene associations. The model was validated using both ClinVar-derived datasets and real-world clinical cohorts. On the challenging MCRD benchmark dataset, GenPhenia achieved 60% Top-1 recall and 80% Top-10 recall, substantially outperforming previously reported methods, which achieved less than 30% Top-10 recall under the same conditions. Clinical case studies across endocrinology, cardiology, and immunology further demonstrate that the model effectively refines gene rankings as phenotypic specificity increases during the diagnostic process.
    CONCLUSIONS: GenPhenia provides a scalable and highly sensitive computational approach for phenotype-driven gene prioritization that aligns with the iterative nature of clinical phenotyping and genomic diagnosis. The framework may facilitate more efficient variant interpretation and support the integration of artificial intelligence methods into clinical genomics workflows for rare disease diagnosis.
    Keywords:  Clinical Genomics; Deep Learning; Gene Prioritization; Graph Neural Networks; Human Phenotype Ontology; Next-Generation Sequencing; Phenotype-Driven Analysis; Rare Disease Diagnosis
    DOI:  https://doi.org/10.1186/s40246-026-01023-9
  21. Genetics. 2026 Nov 13. pii: iyag326. [Epub ahead of print]
      Mild disruptions to mitochondrial function can lead to the activation of an adaptive program that extends animal lifespan. The mitochondrial unfolded protein response (UPRmt) is associated with such conditions that prolong lifespan. We previously discovered that methionine restriction, resulting from the genetic loss of methionine synthase in C. elegans, activated the UPRmt and extended lifespan. Here, we demonstrate that methionine restriction activates the UPRmt and delays aging within the intestine of C. elegans. Using a forward genetics approach, we identified a role for PKC-1, the C. elegans ortholog of protein kinase C epsilon/eta (PKC???), in regulating methionine restriction-associated UPRmt (MetR-UPRmt). PKC-1 activity was required for the increased lifespan and host resistance during infection that was associated with methionine restriction. Strikingly, PKC-1 was not required for UPRmt activation resulting from dysfunctional oxidative phosphorylation, mitochondrial protein translation, or mitochondrial protein import. We find that secretion of neuropeptides from dense-core vesicles is required for MetR-UPRmt activity, consistent with the role of PKC-1 in regulating this form of neurotransmission. We also identify specific neuropeptides (INS-27, INS-34, and INS-35) that positively regulate MetR-UPRmt activity and associated lifespan extension. Mechanistically, we find that neuropeptide signaling regulates MetR-UPRmt activity in part by altering mitochondrial network dynamics. Together, our data suggest a model in which neuropeptide signaling preferentially regulates UPRmt activity and lifespan extension induced by intestinal methionine restriction, but not by other forms of mitochondrial dysfunction.
    Keywords:  UPRmt; lifespan; methionine; mitochondria; neuropeptides; stress signaling
    DOI:  https://doi.org/10.1093/genetics/iyag326
  22. Neurogenetics. 2026 Nov 07. pii: 88. [Epub ahead of print]27(1):
      Mitochondrial diseases (MD) are a heterogeneous group of disorders with a diagnostic rate often below 50%, mostly due to the difficulty of interpreting Variants of Unknown Significance (VUS). ACAD9 is a nuclear gene that encodes a mitochondrial protein involved in fatty acid β-oxidation and the assembly of respiratory complex I. This study aimed to refine the classification of ACAD9 missense VUS through an integrative computational approach combining in silico, evolutionary and structural analysis. A gene-specific dataset of missense pathogenic, benign and uncertain significance variants was curated from public databases (HGMD, ClinVar, GnomAD, UniProt or LOVD) and in-house sequencing data. Thirty-five in silico pathogenicity predictors were retrieved from the dbNSFP v5.3 and benchmarked using the datasets. Predictor performance was evaluated using 10 metrics and the top predictors were integrated with evolutionary conservation (ConSurf), structural modelling (PyMOL, HOPE) and thermodynamic stability analysis (FoldX) to re-evaluate 17 VUS. Predictor performance for ACAD9 variants varied significantly. Because no statistically significant differences were detected among the ten highest-ranked predictors, ClinPred, MetaRNN, PHACTboost, MutationTaster and REVEL were selected as the top stability-informed predictors. The integrative predictive and structural analysis reclassified 8 variants as "likely pathogenic" and 5 as "likely benign", while 4 remained classified as VUS due to conflicting evidence. A gene-specific, multi-layered computational strategy substantially improves VUS classification in ACAD9. These in silico findings provide strong, albeit non-definitive, evidence to guide diagnostic efforts. It should be complemented with functional validation, which remains essential to confirm pathogenicity.
    Keywords:  ACAD9; Bioinformatical analysis; Mitochondrial diseases; Variants of unknown significance
    DOI:  https://doi.org/10.1007/s10048-026-00957-5
  23. Trends Genet. 2026 Nov 13. pii: S0168-9525(26)00268-4. [Epub ahead of print]
      Genomics has advanced rapidly, yet access remains profoundly unequal. The next revolution will not come from better sequencing alone but from a willingness to organize science around those who need it most. If genomics is to improve health, equitable access must become a scientific and ethical imperative.
    Keywords:  clinical sequencing; genomics; health justice; patient partnership; public good; rare disease
    DOI:  https://doi.org/10.1016/j.tig.2026.10.006
  24. Mol Med Rep. 2027 Jan;pii: 11. [Epub ahead of print]35(1):
      Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the accumulation of misfolded α‑synuclein forming Lewy bodies. Emerging evidence highlights mitochondrial dysfunction as an important and early event in PD pathogenesis. Among the key regulators of mitochondrial quality control, PTEN‑induced kinase 1 (PINK1) plays a pivotal role by initiating mitophagy, the selective clearance of damaged mitochondria. Under physiological conditions, PINK1 is rapidly degraded, whereas mitochondrial depolarization stabilizes PINK1 on the outer mitochondrial membrane, where it recruits and activates Parkin, an E3 ubiquitin ligase, to promote mitophagy. Loss‑of‑function mutations in PINK1 also disrupt this process, leading to the accumulation of dysfunctional mitochondria, oxidative stress, abnormal calcium homeostasis and neuronal apoptosis. Furthermore, PINK1 deficiency has been shown to exacerbate α‑synuclein aggregation, impair synaptic transmission and activate neuroinflammatory pathways, collectively accelerating dopaminergic neurodegeneration. Therapeutic strategies aimed at restoring or enhancing PINK1‑mediated mitophagy through pharmacological activation, gene delivery or modulation of parallel pathways‑represent a promising avenue for PD intervention. Continued elucidation of the molecular functions of PINK1 will provide critical insights into mitochondrial homeostasis and novel therapeutic targets for PD.
    Keywords:  PINK1; Parkinson's disease; mitochondrial autophagy
    DOI:  https://doi.org/10.3892/mmr.2026.14069
  25. Mol Metab. 2026 Nov 11. pii: S2212-8778(26)00156-0. [Epub ahead of print] 102472
      Mitochondrial diseases are a heterogeneous group of genetic disorders caused by impaired oxidative phosphorylation (OxPhos). When skeletal muscle is predominantly affected, they are defined as primary mitochondrial myopathies. Although the genetic causes of mitochondrial myopathies and the resulting bioenergetic impairments are well established, the metabolic drivers behind progressive muscle dysfunction remain poorly defined. This gap in knowledge may contribute to the lack of effective treatments for these disorders. OxPhos defective muscle initiates a metabolic response coordinated by systemic signals which results in muscle and adipose tissue wasting. Here, we show ectopic muscle lipid accumulation in a COX10 KO mouse model of mitochondrial myopathy due to inability to oxidize fatty acids in muscle. In both the mouse model and in mitochondrial patients, we find an increase in ceramides, which is mechanistically linked to chronic ER stress, phosphorylation of eIF2α, and activation of ATF4 signaling. We propose that Ph-eIF2α-mediated attenuation of global protein synthesis and ATF4-initiated atrophy pathways contribute to muscle wasting and weakness. Importantly, inhibition of de novo synthesis of ceramides with myriocin reduces ER stress and ATF4 signaling and improves muscle proteostasis, body weight, and motor functions in the COX10 KO mouse. Together, these findings highlight the role of lipid metabolism as a contributor to mitochondrial myopathy and identify lipid-mediated stress pathways that can be targeted therapeutically.
    Keywords:  COX10; ER stress; ceramides; lipid metabolism; mitochondrial myopathy; muscle wasting
    DOI:  https://doi.org/10.1016/j.molmet.2026.102472
  26. MedComm (2020). 2026 Nov;7(11): e71127
      Mitochondria are key regulators of cellular metabolism and innate immunity, and diverse viruses manipulate these organelles during infection. Viral proteins interact with respiratory chain complexes to regulate oxidative phosphorylation (OXPHOS) and reprogram host bioenergetics, thereby influencing viral replication or host antiviral responses. OXPHOS can be directly altered by viral factors or indirectly regulated through virus-induced changes in host metabolism and signaling. Beyond OXPHOS, viral infection perturbs mitochondrial metabolism, dynamics, calcium homeostasis, membrane potential, redox regulation, and apoptosis, linking mitochondrial alterations to viral replication and virus-associated cellular responses. This review focuses on how viruses regulate mitochondrial function, with particular emphasis on OXPHOS while addressing other mitochondrial processes in viral infection. We further distinguish mitochondrial alterations functionally linked to viral infection outcomes from those observed during infection without direct evidence of their effects on viral infection outcomes. Mitochondrial pathways have dual functions during infection, as viruses can hijack these pathways to promote infection, whereas hosts can utilize them to support antiviral responses. By integrating these mechanistic and experimental findings, this review highlights virus-specific patterns of mitochondrial regulation and their functional significance during infection. A mechanistic understanding of these mitochondrial responses provides a basis for identifying mitochondrial pathways as potential antiviral targets.
    Keywords:  innate immunity; metabolic reprogramming; mitochondria; oxidative phosphorylation (OXPHOS); viral replication
    DOI:  https://doi.org/10.1002/mco2.71127
  27. Int J Mol Sci. 2026 Nov 07. pii: 9993. [Epub ahead of print]27(21):
      Mitochondria are critical for bioenergetics, calcium and redox homeostasis, and apoptosis in neurons. Neurons are especially susceptible to mitochondrial malfunction since they are terminally differentiated and have extraordinary energy requirements. Mechanisms such as defective oxidative phosphorylation, altered fission-fusion dynamics, defective mitophagy, impaired axonal transport and excessive reactive oxygen species (ROS) generation are increasingly appreciated as important mechanisms in major neurodegenerative diseases (NDDs) like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD). The review discusses the structure and function of mitochondria with emphasis on oxidative phosphorylation, ROS and reactive nitrogen species (RNS) signalling, calcium-mediated excitotoxicity, lipid metabolism, and apoptotic and non-apoptotic cell-death mechanisms including necroptosis, ferroptosis, pyroptosis and parthanatos. In particular, disease-specific processes are highlighted, such as impaired mitophagy by amyloid β/tau in AD, PTEN-induced kinase 1 (PINK1)/Parkin dysfunction and complex I inhibition in PD, Superoxide Dismutase 1 (SOD1)/C9orf72-associated mitochondrial defects in ALS, and bioenergetic dysfunction by mutant huntingtin in HD. Therapeutic approaches include mitochondria-targeted antioxidants, fusion and biogenesis enhancers, fission inhibitors, inflammasome modulators, Mitochondrial Permeability Transition Pore (mPTP) inhibitors and gene therapy. Also highlighted are recent advancements such as Ubiquitin-Specific Peptidase 30 (USP30) inhibition, intercellular mitochondrial transfer and regulatory approval of a mitochondria-targeted peptide, together with evidence supporting causality and hurdles underpinning clinical translation. Graded against human-genetic, patient-tissue and model-based evidence, mitochondrial dysfunction is best supported as a primary driver in PD and genetic ALS, and as an early amplifier of proteinopathic or mutant-huntingtin toxicity in sporadic AD and HD.
    Keywords:  mitochondria-targeted antioxidants; mitochondrial dynamics; mitochondrial dysfunction; mitophagy; neurodegeneration; oxidative phosphorylation
    DOI:  https://doi.org/10.3390/ijms27219993